Werkgroep Cardiologische centra Nederland

PREVAIL (Follow-up)

A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who Are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
Medicine
Obicetrapib
Population
ASCVD
Phase
III
Starting year
2021

Director of Study

dr. van Ofwegen-Hanekamp (Cardioloog)
Utrecht, Diakonessenhuis